BioPharma Resources

Drug Trial Radar · NCT06642792

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

A Phase I/II Study of AK129 (Bispecific Antibody Targeting LAG-3 and PD-1) Monotherapy or in Combination With AK117 (Anti-CD47 Monoclonal Antibody) in Relapse or Refractory Classic Hodgkin Lymphoma With PD-1/L1 Inhibitor Treatment Failure

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Jan 17, 2025

Primary completion

Nov 2027

Study completion Feb 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy or in combination with AK117 (anti-CD47 monoclonal antibody) in R/R cHL with PD-1/L1 inhibitor treatment failure.

Conditions

  • Classic Hodgkin Lymphoma

Interventions

  • AK129Drug

    Subjects receive AK129 intravenously.

  • AK117Drug

    Subjects receive AK117 intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Number of participants with dose limiting toxicity (DLT)Time frame: Within the first 28 days following the first dose of study treatment.
  2. Phase I/II: Incidence and severity of adverse events (AEs)Time frame: Up to approximately 2 years.
  3. Phase I/II: Objective response rate (ORR)Time frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.